On October 14, 2026, SNA01 Injection, a Category 1 innovative drug jointly submitted for clinical trial authorization by SINOVAC and the Institute of Biophysics, Chinese Academy of Sciences (CAS), rec

On September 28, SINOVAC and Egypt’s GENNVAX launched a technology transfer project for Poliomyelitis Vaccine, Inactivated, Sabin Strains (sIPV) at an event in Beijing. The launch marks the start of t

The 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) opened in Beijing on September 22, 2026, under the theme "Transforming Innovation into Immunizati

BEIJING, China, August 17, 2026 -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited fi

BEIJING, China, August X, 2026 — SINOVAC announced that its Serum-Free Rabies Vaccine for Human Use has received a Drug Registration Certificate from China's National Medical Products Administrati

BEIJING, China, July 31, 2026 — A study evaluating the optimal timing of a booster dose of varicella vaccine among school-aged children has been published in the Chinese Journal of Epidemiology. The r

BEIJING, China, July 31, 2026 — SINOVAC announced that a large-scale prospective cohort study evaluating the effectiveness of itsvaricella vaccine, live has been published in the peer-reviewed journal

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead

BEIJING, June 24, 2026 — SINOVAC and GENNVAX, Egyptian local partner, signed an agreement for the localized production of influenza and Sabin-strain inactivated poliovirus (sIPV) vaccines during the 5

Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading biopharmaceutical enterprise from China, recently hosted more than 100 public health and

BEIJING, China June 15, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it r

Beijing, China - Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, initiated enrollment for a Phase IIIa c

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form

BEIJING, China May 29, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it re

May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The P

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead

DHAKA, Bangladesh, May 13, 2026 — Sinovac Foundation, an affiliate of Sinovac Biotech Ltd. (SINOVAC), has donated 76,616 vials (383,080 doses) of the company’s Poliomyelitis Vaccine (Vero Cell), Inact

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months

BEIJING, April 30, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it filed

Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.